SEC Form 4 · accession 0001209191-16-133850

Audentes Therapeutics, Inc. · BOLD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jonathan Silverstein

Director · 10% Owner

Period of report

Jul 25, 2016

Accepted (ET)

Jul 25, 2016 · 5:08 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001628738

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Jul 25, 2016	C	627,867	—	A	852,105	I	See Footnotes
Common Stock^F4,F2,F3	Jul 25, 2016	C	2,511,441	—	A	3,363,546	I	See Footnotes
Common Stock^F5,F2,F3	Jul 25, 2016	C	1,071,992	—	A	4,435,538	I	See Footnotes
Common Stock^F6,F2,F3	Jul 25, 2016	C	332,766	—	A	4,768,304	I	See Footnotes
Common Stock^F2,F3	Jul 25, 2016	P	33,334	$15.00	A	4,801,638	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series Seed Preferred Stock^F1,F2,F3	—	Jul 25, 2016	C	627,867	D	—	—	Common Stock	627,867	I
Series A Preferred Stock^F4,F2,F3	—	Jul 25, 2016	C	2,511,441	D	—	—	Common Stock	2,511,441	I
Series B Preferred Stock^F5,F2,F3	—	Jul 25, 2016	C	1,071,992	D	—	—	Common Stock	1,071,992	I
Series C Preferred Stock^F6,F2,F3	—	Jul 25, 2016	C	332,766	D	—	—	Common Stock	332,766	I

Explanation of responses

F1Each share of the issuer's Series Seed Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-208842) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
F2These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP IV, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a member of Advisors.
F3Each of GP IV, Advisors, Isaly and the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the reporting person, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
F4Each share of the issuer's Series A Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to a registration statement, and had no expiration date.
F5Each share of the issuer's Series B Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
F6Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.